On August 14, 2023, Revance Therapeutics, Inc. (Nasdaq: RVNC) announced that the United States (U.S.) Food and Drug Administration (FDA) has approved the first therapeutic indication for DAXXIFY® (DaxibotulinumtoxinA-Lanm) for injection for the treatment of cervical dystonia in adults.7 DAXXIFY®, powered by Peptide Exchange Technology™, was previously approved by the FDA for the temporary improvement of glabellar lines (frown lines) in adults in September 2022 and is the first true innovation in neuromodulator product formulation in more than 30 years

This is just the start for DAXXIFY® and in the coming months there will be more information from Revenue as they begin working towards a larger commercial rollout in 2024.

To keep informed directly from Revance about DAXXIFY®, the following link will have the most up-to-date information on product availability – www.hcp.daxxifytherapy.com.